ACELRX PHARMACEUT. DL-01 (F:R5XA) — Market Cap & Net Worth
Market Cap & Net Worth: ACELRX PHARMACEUT. DL-01 (R5XA)
ACELRX PHARMACEUT. DL-01 (F:R5XA) has a market capitalization of $41.69 Million (€35.66 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #22546 globally and #1990 in its home market, demonstrating a 16.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACELRX PHARMACEUT. DL-01's stock price €0.77 by its total outstanding shares 46609618 (46.61 Million).
ACELRX PHARMACEUT. DL-01 Market Cap History: 2015 to 2026
ACELRX PHARMACEUT. DL-01's market capitalization history from 2015 to 2026. Data shows change from $3.71 Billion to $41.69 Million (-34.53% CAGR).
ACELRX PHARMACEUT. DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACELRX PHARMACEUT. DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of R5XA by Market Capitalization
Companies near ACELRX PHARMACEUT. DL-01 in the global market cap rankings as of May 5, 2026.
Key companies related to ACELRX PHARMACEUT. DL-01 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #497 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #531 globally with a market cap of $49.66 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #497 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #531 | Zoetis Inc | NYSE:ZTS | $49.66 Billion | $112.68 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.87 |
ACELRX PHARMACEUT. DL-01 Historical Marketcap From 2015 to 2026
Between 2015 and today, ACELRX PHARMACEUT. DL-01's market cap moved from $3.71 Billion to $ 41.69 Million, with a yearly change of -34.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €41.69 Million | -14.04% |
| 2025 | €48.50 Million | +79.07% |
| 2024 | €27.08 Million | -31.45% |
| 2023 | €39.51 Million | -62.93% |
| 2022 | €106.59 Million | -77.18% |
| 2021 | €467.10 Million | -54.57% |
| 2020 | €1.03 Billion | -51.94% |
| 2019 | €2.14 Billion | -6.08% |
| 2018 | €2.28 Billion | +30.62% |
| 2017 | €1.74 Billion | -36.41% |
| 2016 | €2.74 Billion | -26.00% |
| 2015 | €3.71 Billion | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of ACELRX PHARMACEUT. DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.69 Million USD |
| MoneyControl | $41.69 Million USD |
| MarketWatch | $41.69 Million USD |
| marketcap.company | $41.69 Million USD |
| Reuters | $41.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulat… Read more